Search research articles
Contact Us
Filters
Showing results (341-350 of 406) with videos related to
Page
of 41
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity
J A Sosman, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
Jeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.
Cancer
|
October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
Ahmad A Tarhini, Paul Frankel, Christopher Ruel, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
October 26, 2017
The roles of inflammation and immune mechanisms in Alzheimer's disease
Linda J Van Eldik, Maria C Carrillo, Patricia E Cole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
Aude G Chapuis, Ilana M Roberts, John A Thompson, et al.
Nature Genetics
|
March 29, 2014
Global optimization of somatic variant identification in cancer genomes with a global community challenge
Paul C Boutros, Adam D Ewing, Kyle Ellrott, et al.
British Journal of Cancer
|
June 13, 2001
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
G Somlo, J H Doroshow, T Synold, et al.
Pigment Cell & Melanoma Research
|
May 23, 2025
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma
Stephanie J Wang, Joanne Xiu, Katherine M Butcher, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
September 18, 2016
Emerging Trends in the Etiology, Prevention, and Treatment of Gastrointestinal Anastomotic Leakage
Sami A Chadi, Abe Fingerhut, Mariana Berho, et al.
JAMA
|
June 8, 2006
Sunitinib in patients with metastatic renal cell carcinoma
Robert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Page
of 41
Search research articles
Search
Showing results (341-350 of 406) with videos related to
Sort By:
Page
of 41
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity
J A Sosman, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
Jeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.
Cancer
|
October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
Ahmad A Tarhini, Paul Frankel, Christopher Ruel, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
October 26, 2017
The roles of inflammation and immune mechanisms in Alzheimer's disease
Linda J Van Eldik, Maria C Carrillo, Patricia E Cole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
Aude G Chapuis, Ilana M Roberts, John A Thompson, et al.
Nature Genetics
|
March 29, 2014
Global optimization of somatic variant identification in cancer genomes with a global community challenge
Paul C Boutros, Adam D Ewing, Kyle Ellrott, et al.
British Journal of Cancer
|
June 13, 2001
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
G Somlo, J H Doroshow, T Synold, et al.
Pigment Cell & Melanoma Research
|
May 23, 2025
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma
Stephanie J Wang, Joanne Xiu, Katherine M Butcher, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
September 18, 2016
Emerging Trends in the Etiology, Prevention, and Treatment of Gastrointestinal Anastomotic Leakage
Sami A Chadi, Abe Fingerhut, Mariana Berho, et al.
JAMA
|
June 8, 2006
Sunitinib in patients with metastatic renal cell carcinoma
Robert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Page
of 41